Fellow Americans, it's time to face the truth.
The deep state has engineered an economic disaster not seen since the 1970s, a devastating combination of skyrocketing prices, vanishing jobs, and frozen growth. The "Misery Index" is approaching 1970s crisis levels, and most Americans have no idea what's coming.
Meanwhile, central banks are buying gold at record levels, over 1,000 tons per year for three consecutive years. They've now hoarded 20% of all gold ever mined.
Ask yourself: what do they know that you don't?
As one sovereign wealth strategist warned: "Look at what they're doing, not what they're saying. Central banks are grabbing gold like there's no tomorrow while everyday Americans are left holding increasingly worthless dollars."
The elites are scrambling to secure real, tangible wealth while your purchasing power evaporates. AI technology is poised to eliminate 28% of middle-class jobs while prices continue climbing. And when mortgage rates spike back toward historic highs, millions of Americans could be forced to liquidate homes and retirement accounts.
This is the great wealth extraction scheme, and you're the target.
Genesis Gold Group, America's premier faith-focused Gold IRA company, is fighting back. They've created the FREE Stagflation Time Bomb Report to expose what's really happening and help patriotic Americans protect their families.
Join the Call to Financial Freedom for All Americans: Claim Your FREE Report Here
With 50+ years of combined precious metals expertise and an America First approach rooted in biblical stewardship principles, Genesis Gold Group specializes in converting vulnerable retirement accounts into inflation-protected physical gold IRAs. Whether you're looking to shield your IRA or invest directly in physical gold and silver, their faith-informed strategies are built to help your wealth survive and thrive.
Thousands of patriotic Americans have already taken action:
"We compared a number of Gold IRA companies and went with Genesis Gold Group. Great industry knowledge and their staff were very patient with us during the process. IRA. Their prices and expertise made it an easy decision to invest with them." - J. Schott, Denver, CO
Protect Your Future: Claim Your FREE Stagflation Time Bomb Report Now
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
Written by Nathan Reiff. Publication Date: 3/12/2026.
Key Points
- Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Fortunately, a number of promising treatments have shown significant potential—and with that comes the possibility of substantial sales.
Two smaller biotech companies are enjoying notable share-price momentum thanks to leading oncology medicines. Beyond their therapeutic promise, these drugs may help the firms move toward greater stability and potentially long-term profitability. That said, both companies still face meaningful challenges, making these typical biotech investments high-risk but with the potential for outsized rewards for investors willing to take a chance.
Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle
The rise of the "Useless Class" (Ad)
Famed historian Yuval Noah Harari recently issued a warning that should send a shiver down the spine of every American. He predicts the emergence of a massive new useless class. These aren't just people who are temporarily unemployed. These are people who have become economically irrelevant. As Luke Lango and I just exposed in our recent interview, we have reached the singularity. For the first time in 250 years, intelligence has been decoupled from labor. During America's first 1776 moment, the steam engine replaced muscle. In this new 1776 moment, AI is replacing the human mind.
This is why you see the Magnificent 7 tech giants adding trillions in value while the real economy feels like it's in a death spiral. The divide is widening. On one side: the useless class who cling to old-world skills. On the other: the new aristocracy who own the assets of the technological republic. Luke and I have identified the three specific money moves our research indicates you must make to ensure you stay on the winning side of this divide.
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked broader market weakness in early March, surging nearly 37% in a week when the S&P 500 slipped about 1%. That added to IOVA's year-to-date performance, which has more than doubled. Still, with a consensus price target of $8.88, Wall Street sees more upside—that target implies another roughly 71% potential gain from current levels.
The main catalyst for Iovance's rally is its T-cell immunotherapy Amtagvi, approved in the United States in 2024 for certain types of melanoma. Amtagvi has built momentum in sales, and the company expects additional approvals in the EU, U.K., and other jurisdictions. When administered with Proleukin, Iovance's IL-2 immunotherapy, management believes Amtagvi could achieve more than $1 billion in U.S. peak sales.
Amtagvi's potential may extend beyond melanoma. The drug has received FDA Fast Track designation for non-small cell lung cancer and could be investigated for other tumor types.
Iovance also benefited from a Q4 2025 earnings report released in late February that showed narrower-than-expected losses per share and about $5 million in revenue. For the full year, revenue rose roughly 30% year-over-year.
Iovance remains a relatively small biotech (about a $2 billion market cap) and its stock is still viewed as speculative. Analysts are cautious: roughly half of its coverage rates it a Hold or Sell. A key risk is Amtagvi's manufacturing model. Because the therapy is personalized, production is complex and costly, which could constrain margins and slow the path to profitability even as demand grows.
Massive Sales Growth for ImmunityBio's Bladder Cancer Drug
ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance dwarfs that decline—IBRX shares are up nearly 300% in 2026 alone. Analysts have a price target of $13.60, roughly 70% above the stock's current level even after the big run-up.
ImmunityBio's primary growth driver is Anktiva, a therapy for certain bladder cancers. In February, shares climbed after the EU regulator granted conditional marketing authorization—the latest in a series of approvals worldwide.
Anktiva has been driving strong revenue growth: the drug produced $113 million in sales last year, a roughly 700% year-over-year increase. ImmunityBio is also exploring additional indications for Anktiva, which could expand its addressable market.
Despite the dramatic stock appreciation, IBRX remains speculative and risky. The company reported a sizable full-year net loss of $351 million for 2025 as R&D and operating expenses continued to climb. Still, Wall Street sentiment is relatively bullish: six of seven analysts covering the stock rate it a Buy or equivalent.
Both Iovance and ImmunityBio illustrate the upside and downside of small-cap oncology biotech investing—significant commercial potential from breakthrough medicines, paired with execution, manufacturing and financing risks that can keep these stocks volatile.
5 Stocks Racing Ahead as AI Supercharges Robotics
Authored by Ryan Hasson. Originally Published: 3/2/2026.
Key Points
- Artificial intelligence is accelerating robotics innovation, enabling faster training, greater autonomy, and real-time adaptability across industries.
- Companies like Tesla, NVIDIA, Deere, Teradyne, and Intuitive Surgical are embedding AI directly into machines, compressing development cycles and expanding real-world applications.
- As AI scales globally, robotics is shifting from incremental automation to intelligent systems, creating long-term structural growth opportunities across multiple sectors.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
Robotics has steadily gained traction over the past decade, and the last five years have marked a clear inflection point. Adoption across industrial, defense, healthcare, logistics, and even consumer applications has accelerated meaningfully. The primary catalyst behind this shift is artificial intelligence.
AI is not just enhancing robotics; it is fundamentally redefining it.
Elon's Private AI Empire: The Backdoor Under $100 (Ad)
Elon Musk's AI Everywhere project isn't inside Tesla—it's a private venture with a global network of 150+ facilities embedding autonomous AI into devices everywhere, and Musk believes this could propel Tesla to become the most valuable company ever, worth more than Apple, Microsoft, Nvidia, Amazon, and Google combined. Private ventures like this are usually locked for elites, but I've found a legitimate brokerage backdoor under $100 with no special requirements, just a regular account, and this private play follows the same playbook as PayPal, SpaceX, Tesla, and xAI using Tesla's proven autonomous AI copy-pasted across the world.
See the 3 steps to profit before the summer regulatory shiftMachine learning, computer vision, and generative AI are transforming robots from rigid, preprogrammed machines into adaptive systems capable of learning, reasoning, and operating autonomously. Breakthroughs that once took years of incremental improvement are now occurring in compressed timeframes.
Generative AI lets robots train in simulated environments at high speed instead of relying solely on physical trial and error. Rather than programming every movement manually, developers can expose robots to millions of virtual scenarios in a fraction of the time. And natural-language interfaces now allow workers to instruct machines conversationally, dramatically reducing deployment friction.
In short, AI is acting as an accelerant across the robotics landscape, pushing both capabilities and commercialization forward more quickly. These five stocks are advancing more rapidly as a direct result of AI integration.
Tesla: From Autonomous Vehicles to Humanoid Robots
Tesla (NASDAQ: TSLA) may be best known as an electric vehicle manufacturer, but at its core it is arguably among the world's most visible consumer-facing robotics companies.
Its autonomous vehicles are effectively mobile robots operating in uncontrolled real-world environments. Tesla's Full Self-Driving system relies on neural networks trained on billions of miles of driving data. That same AI backbone powers Optimus, its humanoid robot initiative.
Optimus is designed to perform repetitive, dangerous, or labor-intensive tasks across factories, warehouses, and eventually households. It uses computer vision, reinforcement learning, and Tesla's custom AI chips to interpret surroundings and navigate complex environments. The real breakthrough lies not only in mechanical engineering but also in the software stack that enables Optimus to learn and improve over time.
CEO Elon Musk has described Optimus as potentially more transformative than Tesla's vehicle business in the long run. The company has discussed targets for eventual mass production measured in the millions of units annually, with a projected consumer price point between $20,000 and $30,000.
Tesla recently announced plans to wind down production of its high-end Model S and Model X lines to free up factory capacity for a dedicated Optimus assembly line. That strategic pivot signals confidence that AI-powered robotics could become a central pillar of the company's future growth.
NVIDIA: The Computing Backbone of Robotics
NVIDIA (NASDAQ: NVDA) is the most obvious AI beneficiary, but its impact on robotics runs deeper than headline GPU demand suggests.
Advanced robotics requires massive computing resources for perception, localization, mapping, and decision-making. Without high-performance processors capable of running complex neural networks in real time, modern robotics would stall.
NVIDIA's Jetson platform is purpose-built for edge AI and is widely deployed in robots, drones, and autonomous systems. These modules process visual, spatial, and sensor data locally, enabling low-latency decision-making—critical in environments where split-second reactions matter.
Beyond hardware, NVIDIA's Isaac robotics development platform lets engineers simulate robotic systems in photorealistic virtual environments. Developers can train robots in simulation before deploying them in the physical world, dramatically accelerating innovation cycles while lowering risk and cost.
As robotic systems grow more intelligent and autonomous, NVIDIA remains a foundational infrastructure provider. It is not simply participating in the growth of robotics; it is enabling it.
Deere & Company: Smart Farming at Scale
Deere & Company (NYSE: DE) might surprise some investors on a robotics list, but the agricultural leader has quietly transformed into a technology-driven automation company.
Labor shortages, rising input costs, and the need for greater efficiency have pushed agriculture toward autonomy. Deere's fully autonomous 8R tractor can operate without a driver, using AI-powered computer vision and advanced GPS guidance to navigate fields with precision.
Following its acquisition of Blue River Technology, Deere launched its See & Spray system, which uses machine learning to distinguish crops from weeds in real time. Instead of blanket herbicide spraying, the system applies chemicals only where needed, reducing usage and improving environmental efficiency.
AI also powers Deere's broader ecosystem through the John Deere Operations Center, which aggregates farm data and delivers predictive analytics to optimize planting, harvesting, and maintenance decisions.
The company has effectively shifted from a heavy-equipment manufacturer to a data-driven automation platform for agriculture. As AI models improve, the productivity gains across farming operations could accelerate, reinforcing Deere's long-term positioning.
Teradyne: Testing the AI Revolution
Teradyne (NASDAQ: TER) operates at a critical junction of semiconductor complexity and industrial automation. As AI chips become more powerful, dense, and performance-sensitive, testing requirements intensify.
Teradyne's automated test equipment validates advanced semiconductors for data centers, autonomous systems, and robotics applications.
AI-driven demand has become a primary growth driver. In Q4 2025, the company reported EPS of $1.80, well above consensus, while revenue rose nearly 44% year over year to $1.08 billion. AI-related demand, including data center expansion, accounted for a majority of quarterly revenue.
Beyond semiconductor testing, Teradyne owns collaborative robotics businesses that manufacture industrial robotic arms and mobile robots. These systems increasingly incorporate AI to improve flexibility in factories and logistics centers.
With AI adoption scaling across industries, both chip testing and AI-enabled robotics solutions position Teradyne as a beneficiary of the broader automation wave—a classic picks-and-shovels play.
Intuitive Surgical: AI in the Operating Room
Intuitive Surgical (NASDAQ: ISRG) is a pioneer in robotic-assisted surgery and remains the global leader in minimally invasive procedures.
Its da Vinci Surgical System has already improved surgical precision by giving physicians enhanced visualization, dexterity, and control. Now, AI is deepening that advantage.
Rather than operating solely as a hardware manufacturer, Intuitive is building an intelligent surgical ecosystem. AI algorithms analyze intraoperative data in real time, enhance imaging clarity, and provide insights that help surgeons make more precise decisions.
The company's Ion endoluminal system, for example, uses AI-powered computer vision to navigate to difficult-to-reach lung nodules, compensating for discrepancies between preoperative imaging and live anatomy. This improves diagnostic accuracy and patient outcomes.
As the installed base of robotic systems grows globally, the accumulation of surgical data further strengthens Intuitive's AI models. That flywheel effect could expand the company's competitive moat over time.
The Acceleration Effect
Robotics is not new. What is new is the velocity of innovation.
AI is compressing development timelines, improving adaptability, and broadening commercial use cases across nearly every sector. Whether in autonomous vehicles, agriculture, semiconductor testing, industrial automation, or operating rooms, AI acts as a multiplier.
For investors, the theme is not just robotics adoption but robotics acceleration driven by AI integration.
These five companies sit at the forefront of that shift, advancing faster because intelligence is now embedded directly into the machines themselves.
to bring you the latest market-moving news.
This email communication is a sponsored email from Genesis Gold Group, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
Copyright 2006-2026 MarketBeat Media, LLC dba TickerReport.
345 N Reid Place, Suite 620, Sioux Falls, South Dakota 57103. USA..
0 Response to "JPMorgan confirms stagflation risk has doubled. Is your retirement ready?"
Post a Comment